Brief: Inventiva Announces Screening Of First Patient In Phase IIa Combination Trial With Lanifibranor, Empagliflozin

Inventiva SA

08/07/2022 06:25

July 8 (Reuters) - Inventiva  IVAA.PA :
    * INVENTIVA ANNOUNCES SCREENING OF FIRST PATIENT IN THE U.S.
IN
LEGEND, A PHASE IIA COMBINATION TRIAL WITH LANIFIBRANOR AND
EMPAGLIFLOZIN IN PATIENTS WITH NASH AND T2D
    * PHASE IIA PROOF-OF-CONCEPT STUDY IS DESIGNED TO ASSESS
SAFETY
AND EFFICACY OF LANIFIBRANOR IN COMBINATION WITH SGLT2 INHIBITOR
EMPAGLIFLOZIN FOR TREATMENT OF PATIENTS WITH NON-CIRRHOTIC
NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND TYPE-2 DIABETES (T2D)
    * PRIMARY EFFICACY ENDPOINT WILL BE BASED ON IMPROVEMENT IN
HBA1C
    * SECONDARY EFFICACY ENDPOINTS INCLUDE CHANGES IN LIVER
ENZYMES,
MARKERS OF GLYCEMIC CONTROL, LIPID METABOLISM, INFLAMMATION AND
BODY FAT COMPOSITION
    * PUBLICATION OF TOPLINE RESULTS IS EXPECTED IN SECOND HALF
OF
2023

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE8B0q8j
    
 Further company coverage: [ IVAA.PA ] 
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))